Nyrada Half Year FY2025 Results

Highlights:
•Development of lead drug candidate NYR-BI03 continues:
-Preclinical efficacy study demonstrated 86% cardioprotective effect following myocardial ischemia-reperfusion injury.
-Phase Ia first-in-human clinical trial approved to commence.
-Composition of matter patent applications submitted.

•Sound financial position:
-Fully subscribed placement successfully raised AU$3.29 million equity (before costs).
-Securities Purchase Plan raised AU$0.09 million (before costs)
-R&D tax rebate of AU$1.24 million received.
-Cash balance of AU$5.71 million at 31 December 2024.